Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)

NACompletedINTERVENTIONAL
Enrollment

1,480

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

March 17, 2021

Study Completion Date

March 17, 2021

Conditions
Malaria
Interventions
DRUG

Artemether-lumefantrine

"One tablet AL contains 20 mg artemether and 120 mg lumefantrine~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."

DIETARY_SUPPLEMENT

Multivitamin

"One tablet contains Vitamin-A : 5000 USP units, Vitamin D: 400 USP Units, Ascorbic acid: 75 mg, Thiamine Mononitrate: 2 mg, Riboflavin: 3 mg, Niacin amide: 20 mg.~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."

Trial Locations (2)

Unknown

Pursat Referral Hospital/Kravanh Health Center, Pursat

Stung Treng Referral Hospital/Siem Pang Health Center, Stung Treng

All Listed Sponsors
collaborator

Global Fund

OTHER

lead

University of Oxford

OTHER

NCT04041973 - Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia) | Biotech Hunter | Biotech Hunter